A comparative evaluation of the efficacy and safety of Latanoprost-Optic and Xalatan used as monotherapy and combined with Dorzolamide-Optic for primary open-angle glaucoma under clinical practice conditions

Abstract

The number of ophthalmic antihypertensive drugs available in Russia is steadily increasing, which complicates the choice to be made by ophthalmologist practitioners. Purpose: to compare the efficacy and safety of the domestically produced drug Latanoprost-Optic with the original drug Xalatan used as monotherapy or combined with the domestic drug Dorzolamide-Optic in patients with primary open-angle glaucoma (POAG). Material and methods. 116 completed cases of patients aged 69.3 ± 5.7 with newly diagnosed POAG were retrospectively analyzed, whereby we assessed the efficacy, safety and tolerability of monotherapy with Latanoprost-Optic or Xalatan and their combinations with Dorzolamide-Optic. Results. Latanoprost-Optic efficacy is no worse than that of Xalatan as it reduces intraocular pressure (IOP) by 33.8%, and has a comparable safety and tolerability profile. More than 72% of patients rate the tolerability of treatment with LatanoprostOptic as very good or good. An additional hypotensive effect of Dorzolamide-Optic added to latanoprost is 2.6–2.8 mm Hg, or 13.2–14.4% and involves no significant effect on the safety profile and tolerability of therapy. Conclusion. Latanoprost-Optic can be considered as a more affordable alternative to the original drug. If the target IOP values cannot be achieved by latanoprost alone, its combination with DorzolamideOptic is recommended, especially for patients with chronic diseases of the respiratory system and the cardiovascular system.